Loading company
Dyne Therapeutics, Inc.
DYN · Nasdaq · ·
Next earnings: November 4, 2026
$16.22-0.8%Sep 29 close
- 1M
- -35.3%
- 6M
- -5.1%
- 1Y
- +28.2%
- 5Y
- -0.9%
DYN · Nasdaq · ·
Next earnings: November 4, 2026
$16.22-0.8%Sep 29 close
Dyne Therapeutics, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$178.6M | -$110.9M | -61.07% |
| Profit per share | -$1.08 | -$0.97 | -11.34% |
| Free Cash Flow | -$131.8M | -$94.8M | -39.08% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Dyne Therapeutics, Inc. has no earnings call transcript available.
“We continue to make significant progress as we execute on our goal of delivering functional improvement for people living with genetically driven neuromuscular diseases,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Dyne Therapeutics, Inc.’s Item 2.02 8-K filed July 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.